Journal
CARCINOGENESIS
Volume 32, Issue 5, Pages 643-649Publisher
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgr019
Keywords
-
Categories
Funding
- United States National Cancer Institute [1R01CA099985, 1R01CA123088, 1R01CA0156685]
- Marsha Rivkin Center for Ovarian Cancer Research
- Ovarian Cancer Research Fund
Ask authors/readers for more resources
The role of CD4(+) T helper (Th) 17 cells in malignancy is currently under debate. However, upon closer scrutiny, it becomes apparent that this discussion includes not only evaluations of Th17 cells but also IL-17(+) cells from other immune populations, the cytokine interleukin (IL)-17 itself (both endogenous and exogenous) and IL-23. Further complicating the matter are occasionally conflicting results of studies in humans versus those in mice and contradictory data from immunocompetent versus immunodeficient mice. To better understand the role of Th17 cells in the tumor-bearing host, we focus first upon those studies investigating Th17 cells in patients and then those in mice, all the while keeping in mind that variables such as tumor-initiating agents, a pre-existing inflammatory environment and the immune competence of the host may have direct effects upon this T-cell subset. In this review, we will describe the phenotype of tumor-associated Th17 cells, review those studies that have examined the population directly, and finally, briefly discuss the studies involving Th17-associated signature cytokines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available